ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
13.70
+0.20 (1.48%)
Aug 10, 2026, 3:36 PM EDT - Market open
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 111 employees as of June 30, 2026. The number of employees decreased by 17 or -13.28% compared to the same quarter last year.
Employees
111
Change
-17
Growth
-13.28%
Revenue / Employee
n/a
Profits / Employee
-$1,264,423
Market Cap
1.42B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 111 | -17 | -13.28% |
| Mar 31, 2026 | 104 | -18 | -14.75% |
| Dec 31, 2025 | 104 | -11 | -9.57% |
| Sep 30, 2025 | 106 | -6 | -5.36% |
| Jun 30, 2025 | 128 | 21 | 19.63% |
| Mar 31, 2025 | 122 | 20 | 19.61% |
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Sep 30, 2024 | 112 | 19 | 20.43% |
| Jun 30, 2024 | 107 | 18 | 20.22% |
| Mar 31, 2024 | 102 | 14 | 15.91% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Sep 30, 2023 | 93 | 5 | 5.68% |
| Jun 30, 2023 | 89 | 6 | 7.23% |
| Mar 31, 2023 | 88 | 9 | 11.39% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Sep 30, 2022 | 88 | 14 | 18.92% |
| Jun 30, 2022 | 83 | 13 | 18.57% |
| Mar 31, 2022 | 79 | 13 | 19.70% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Immatics | 678 |
| MannKind | 592 |
| Vir Biotechnology | 367 |
| Monte Rosa Therapeutics | 187 |
| Innoviva | 159 |
| ArriVent BioPharma | 77 |
| Savara | 70 |
ORIC News
- 9 hours ago - Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright - TheFly
- 2 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 days ago - Oric Pharmaceuticals reports Q2 EPS (38c), consensus (36c) - TheFly
- 6 days ago - ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates - GlobeNewsWire
- 6 days ago - ORIC Pharmaceuticals Earnings release: Q2 2026 - Filings
- 6 days ago - ORIC Pharmaceuticals Quarterly report: Q2 2026 - Filings
- 21 days ago - ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewsWire
- 26 days ago - Oric Pharmaceuticals initiates Himalayas-1 trial - TheFly